Natera

YTD

ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

CEO

Stephen Leonard Chapman

CEOStephen Leonard Chapman

Employees

6,140

Employees6,140

Headquarters

Austin, Texas

HeadquartersAustin, Texas

Founded

2003

Founded2003

Employees

6,140

Employees6,140

NTRA Key Statistics

Market cap

38.20B

Market cap38.20B

Price-Earnings ratio

-160.98

Price-Earnings ratio-160.98

Dividend yield

—

Dividend yield—

Average volume

1.09M

Average volume1.09M

High today

$272.14

High today$272.14

Low today

$261.01

Low today$261.01

Open price

$264.04

Open price$264.04

Volume

109.80K

Volume109.80K

52 Week high

$288.04

52 Week high$288.04

52 Week low

$131.81

52 Week low$131.81

Stock Snapshot

Natera(NTRA) stock is priced at $266.73, giving the company a market capitalization of 38.2B. It carries a P/E multiple of -160.98.

As of 2026-07-23, Natera(NTRA) stock has fluctuated between $261.01 and $272.14. The current price stands at $266.73, placing the stock +2.2% above today's low and -2.0% off the high.

The Natera(NTRA)'s current trading volume is 109.8K, compared to an average daily volume of 1.09M.

During the past year, Natera(NTRA) stock moved between $131.81 at its lowest and $288.04 at its peak.

NTRA News

Investing.com 1d

Natera’s Signatera test outperforms standard MCC monitoring tool - Investing.com

...

TipRanks 1d

Natera reports results from multicenter study in MCC

Natera (NTRA) announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma, or MCC, published in JAMA Dermatology. The st...

Nasdaq 2d

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

It's been a bit of a tough year for Cathie Wood, the maverick fund manager and chief of Ark Invest. She forged a reputation as a risk taker and won a lot of fol...

Analyst ratings

88%

of 24 ratings

Buy

87.5%

Hold

12.5%

Sell

More NTRA News

Simply Wall St 5d

Natera On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued

Natera (NTRA) stock is in focus after two key developments: a final local coverage determination expanding Prospera transplant test access and stronger than exp...

Simply Wall St 7d

The Bull Case For Natera Could Change Following New Signatera JAMA Oncology Evidence On MRD-Guided Chemotherapy

Natera, Inc. recently reported that Monica Bertagnolli resigned from its Board of Directors on July 1, 2026, following her appointment to the National Academy o...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Flowserve

iShares MSCI Emerging Mar…

Linde plc

CSX

Alcoa

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.